2020–2021 BCSC Basic and Clinical Science Course™
1 Update on General Medicine
Chapter 11: Behavioral and Neurologic Disorders
Each year, 1 in 5 adults is affected with a mental health disorder, of which only half are ever diagnosed by a physician.
Newer therapeutic agents for psychiatric diseases allow for more effective treatment with generally fewer adverse effects compared with older agents.
Visual impairment almost doubles the risk of acquired depression.
Second-generation antipsychotics (SGAs) such as olanzapine, quetiapine, and clozapine may be associated with the onset or worsening of diabetes mellitus and its associated ocular findings.
The use of the antiepileptic medication vigabatrin is associated with irreversible and often asymptomatic concentric visual field loss in up to 50% of patients.
Some new treatments for Parkinson disease may be neuroprotective and are therefore considered potential disease-modifying agents.
Excerpted from BCSC 2020-2021 series: Section 1 - Update on General Medicine. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.